We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRV:NYSEThe Travelers Companies, Inc. analysis

Data as of Oct 15, 2026 - not real-time

Latest price
$377.82
Risk: low
3/10Low risk

Summary

At $377.82, The Travelers Companies, Inc. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have gained 3.8%. Momentum indicators put RSI at 63.8 (approaching overbought) with MACD reading bullish. Price has been bracketed by support at $353.79 and resistance at $382.97.
Valuation screens as undervalued: a P/E of 10.0 sits below the sector average of 15.5. The average analyst target implies 4.5% below today's level. The 1.34% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 17.9%, a beta of -0.14 and a maximum drawdown of 10.2%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
All three time horizons resolve to buy, carrying 7/10 conviction.

Top market events

  • Revenue hit USD 12.15 billion in the second quarter of 2026. Travelers Companies stock costs EUR 323
  • Travelers Companies stock is at EUR 329.35 pre-market at Lang & Schwarz on October 12, 2026. The quo
  • At the close on September 4, 2026, Travelers Companies stock finished higher on the NYSE, with the m

Market outlook

Short term

< 1 year

Positive

Model confidence6/106 out of 10

Key factors

  • Trading above the 200-day average of 323.17
  • MACD momentum is positive
  • RSI at 63.8 is in neutral territory

Medium term

1–3 years

Positive

Model confidence6/106 out of 10

Key factors

  • P/E of 10.0 versus sector average of 15.5
  • Trading above the 200-day average of 323.17
  • MACD momentum is positive

Long term

> 3 years

Positive

Model confidence7/107 out of 10

Key factors

  • P/E of 10.0 versus sector average of 15.5
  • Profit margin of 17.0% is healthy
  • Return on equity of 26.5%

Key metrics

Financial health

Revenue Growth0.30%
Profit Margin16.95%
P/E Ratio10.0
ROE26.51%
ROA4.78%
Debt/Equity27.38
P/B Ratio2.4
Op. Cash Flow$11.0B
Free Cash Flow$14.8B
Industry P/E15.5

Technical analysis

TrendNeutral
RSI63.8
Support$353.79
Resistance$382.97
MA 20$366.09
MA 50$369.19
MA 200$323.17
MACDBullish
VolumeDecreasing
Fear & Greed Index90.36

Valuation

Fair Value$838.09
Target Price$360.67
Upside/Downside-4.54%
GradeUndervalued
TypeValue
Dividend Yield1.34%

Risk assessment

Beta-0.14
Volatility17.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.